Cardiorenal syndrome

Heart Failure Clinics

Volumn 10, Issue 2, 2014, Pages 251-280

  Ronco, Claudio ^a   Di Lullo, Luca ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UOC Medicina laterna   (Italy)

Author keywords

Acute decompensated heart failure; Acute kidney disease; Cardiorenal syndrome; Chronic heart failure; Chronic kidney disease; Sepsis

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; BISOPROLOL; BRADYKININ; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CREATININE; ENALAPRIL; ENDOTHELIN; FIBROBLAST GROWTH FACTOR 23; GALECTIN 3; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN; VALSARTAN;

ACIDEMIA; ACTION POTENTIAL; ACUTE CORONARY SYNDROME; APOPTOSIS; ARTERIAL PRESSURE; ARTERY COMPLIANCE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIORENAL SYNDROME; CARDIOVASCULAR RISK; CELL MEMBRANE POTENTIAL; CENTRAL VENOUS PRESSURE; CHRONIC KIDNEY DISEASE; CIRCULATION; COLOR ULTRASOUND FLOWMETRY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ATHEROSCLEROTIC HEART DISEASE; CORONARY CALCIFICATION; DIASTOLIC DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART CALCIFICATION; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE CONDUCTION; HEMODYNAMICS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; IATROGENIC DISEASE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY SIZE; LEUKOCYTE; LEUKOCYTE COUNT; LIQUID; LUNG CONGESTION; LYMPHOCYTE; MACROPHAGE; MALNUTRITION; MEMBRANE STEADY POTENTIAL; METABOLIC ACIDOSIS; METABOLISM; MONOCYTE; MORTALITY; MYOCARDIAL DISEASE; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PATHOGENESIS; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PREVALENCE; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SEPSIS; SEPTIC SHOCK; SMOOTH MUSCLE FIBER; SUDDEN DEATH; TISSUE PRESSURE; TYPE 1 CARDIORENAL SYNDROME; TYPE 2 CARDIORENAL SYNDROME; TYPE 3 CARDIORENAL SYNDROME; TYPE 4 CARDIORENAL SYNDROME; TYPE 5 CARDIORENAL SYNDROME; UREMIA; CARDIO-RENAL SYNDROME; CLASSIFICATION;

CARDIO-RENAL SYNDROME; HUMANS;

EID: 84896389228     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.12.003     Document Type: Review

References (219)

1. Ronco C. The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med 2011, 1:3-4.
2. Bargshaw S.M., Cruz D.M., Aspromonte N., for the Acute Dialysis Quality Initiative (ADQI) Consensus Group, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010, 25:1406-1416.
3. Damman K., Navis G., Voors A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. JCard Fail 2007, 13:599-608.
4. McCullough P.A. Cardiorenal syndromes: pathophysiology to prevention. Int J Nephrol 2010, 2010:762590.
5. Ronco C. Cardiorenal syndromes: definition and classification. Contrib Nephrol 2010, 164:33-38.
6. Eren Z., Ozveren O., Buvukoner E., et al. Asingle-centre study of acute cardiorenal syndrome: incidence, risk factors and consequences. Cardiorenal Med 2012, 2:168-176.
7. Hanada S., Takewa Y., Mizuno T., et al. Effect of the technique for assisting renal blood circulation on ischemic kidney in acute cardiorenal syndrome. JArtif Organs 2012, 15:140-145.
8. Stevenson L.W., Perloff J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989, 261:884-888.
9. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. JAm Coll Cardiol 2009, 53:589-596.
10. Uthoff H., Breidthardt T., Klima T., et al. Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 2011, 13:432-439.
11. Braam B., Cupples W.A., Joles J.A., et al. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 2012, 17:161-175.
12. De Silva R., Loh H., Rigby A.S., et al. Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography. Am J Cardiol 2007, 100:273-279.
13. Nohria A., Tsang S.W., Fang J.C., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. JAm Coll Cardiol 2003, 41:1797-1804.
14. Machnik A., Neuhofer W., Jantsch J., et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009, 15:545-552.
15. Virzì G.M., Torregrossa R., Cruz D.N., et al. Cardiorenal syndrome type 1 may be immunologically mediated: a pilot evaluation of monocyte apoptosis. Cardiorenal Med 2012, 2:33-42.
16. Kraut E.J., Chen S., Hubbard N.E., et al. Tumor necrosis factor depresses myocardial contractility in endotoxemic swine. JTrauma 1999, 46:900-906.
17. Van Sloten T.T., Pijpers E., Steouwer C.D., et al. Metformin-associated lactic acidosis in a patient with normal kidney function. Diabetes Res Clin Pract 2012, 96:57-58.
18. Arroio D., Melero R., Panizo M., et al. Metformin-associated acute kidney injury and lactic acidosis. Int J Nephrol 2011, 2011:749-763.
19. Xu G., Ahn J., Chang S., et al. Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. JBiol Chem 2012, 287:4808-4817.
20. Prawle J.R., Liu Y.I., Licari E., et al. Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care 2011, 15:R172.
21. Mc Donagh T.A., Komajda M., Maggioni A.P., et al. Clinical trials in acute heart failure: simpler solution to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure. Eur J Heart Fail 2011, 13:1253-1260.
22. Prowle J.R., Echeverri J.E., Ligabo E.V., et al. Fluid balance and acute kidney injury. Nat Rev Nephrol 2010, 6:107-115.
23. Latouche C., El Moghrabi S., Messaoudi S., et al. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 2012, 59:966-972.
24. Maisel A., Xue Y., Shah K., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011, 4:613-620.
25. Shah R.V., Truong Q.A., Gaggin H.K., et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012, 33:2197-2205.
26. Maisel A.S., Katz N., Hillege H.L., Acute Dialysis Quality Initiative consensus group, et al. Biomarkers in kidney and heart disease. Nephrol Dial Transplant 2011, 26:62-74.
27. Aldous S.J., Richards A.M., Troughton R., et al. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. JCard Fail 2012, 18:304-310.
28. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. JCard Fail 2008, 14:732-738.
29. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
30. Dhillon O.S., Narayan H.K., Quinn P.A., et al. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011, 161:1163-1170.
31. Tojo A., Gross S.S., Zhang L., et al. Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. JAm Soc Nephrol 1994, 4:1438-1447.
32. Singh P., Okusa M.D. The role of tubuloglomerular feedback in the pathogenesis of acute kidney injury. Contrib Nephrol 2011, 174:12-21.
33. Campbell C.Y., Clarke W., Park H., et al. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 2009, 104:389-392.
34. Lassus J.P., Nieminen M.S., Peuhkurinen K., FINN-AKVA study group, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010, 31:2791-2798.
35. Cruz D.N., Gaiao S., Maisel A., et al. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med 2012, 50:1533-1545.
36. Alvelos M., Lourenço P., Dias C., et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2013, 165(1):51-55.
37. Maisel A.S., Mueller C., Fitzgerald R., et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851.
38. Alvelos M., Pimentel R., Pinho E., et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol 2011, 6:476-481.
39. Aghel A., Shrestha K., Mullens W., et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. JCard Fail 2010, 16:49-54.
40. Collins S.P., Hart K.W., Lindsell C.J., et al. Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail 2012, 14:1020-1029.
41. Valente M.A., Damman K., Dunselman P.H., et al. Urinary proteins in heart failure. Prog Cardiovasc Dis 2012, 55:44-55.
42. Di Somma S., De Berardinis B., Bongiovanni C., et al. Use of BNP and bioimpedance to drive therapy in heart failure patients. Congest Heart Fail 2010, 16:S56-S61.
43. Parrinello G., Paterna S., Di Pasquale P., et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. JCard Fail 2008, 14:676-686.
44. Milzman D., Napoli A., Hogan C., et al. Thoracic impedance vs chest radiograph to diagnose acute pulmonary edema in the ED. Am J Emerg Med 2009, 27:770-775.
45. Whellan D.J., Droogan C.J., Fitzpatrick J., et al. Change in intrathoracic impedance measures during acute decompensated heart failure admission: results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study. JCard Fail 2012, 18:107-112.
46. Di Lullo L., Floccari F., Granata A., et al. Ultrasonography: Ariadne's thread in the diagnosis of cardiorenal syndrome. Cardiorenal Med 2012, 2(1):11-17.
47. Voors A.A., Davison B.A., Felker G.M., Pre-RELAX-AHF study group Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 2011, 13:961-967.
48. Shirakabe A., Hata N., Kobayashi N., et al. Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 2013, 77(3):687-696.
49. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. JCard Fail 2007, 13(6):422-430.
50. Hebert K., Dias A., Delgado M.C., et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail 2010, 12(8):861-865.
51. Cruz D.N., Bagshaw S.M. Heart-kidney interaction: epidemiology of cardiorenal syndromes. Int J Nephrol 2010, 2011:351291.
52. Cruz D.N., Schmidt-Ott K.M., Vescovo G., et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013, 182:117-136.
53. Setoguchi S., Stevenson L.W., Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007, 154(2):260-266.
54. Tanaka K., Ito M., Kodama M., et al. Longitudinal change in renal function in patients with idiopathic dilated cardiomyopathy without renal insufficiency at initial diagnosis. Circ J 2007, 71(12):1927-1931.
55. Bongartz L.G., Cramer M.J., Doevendans P.A., et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005, 26(1):11-17.
56. Merrill A.J., Morrison J.L., Branno E.S. Concentration of renin in renal venous blood in patients with chronic heart failure. Am J Med 1946, 1(5):468.
57. Kishimoto T., Maekawa M., Abe Y., et al. Intrarenal distribution of blood flow and renin release during renal venous pressure elevation. Kidney Int 1973, 4(4):259-266.
58. Remuzzi G., Cattaneo D., Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. JAm Soc Nephrol 2008, 19(8):1459-1462.
59. Onozato M.L., Tojo A., Kobayashi N., et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007, 22(5):1314-1322.
60. Colombo P.C., Ganda A., Lin J., et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012, 17(2):177-190.
61. Colombo P.C., Onat D., Sabbah H.N. Acute heart failure as "acute endothelitis"-interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail 2008, 10(2):170-175.
62. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113(5):671-678.
63. Halbesma N., Jansen D.F., Heymans M.W., et al. Development and validation of a general population renal risk score. Clin J Am Soc Nephrol 2011, 6(7):1731-1738.
64. Tangri N., Stevens L.A., Griffith J., et al. Apredictive model for progression of chronic kidney disease to kidney failure. JAMA 2011, 305(15):1553-1559.
65. Khan N.A., Ma I., Thompson C.R., et al. Kidney function and mortality among patients with left ventricular systolic dysfunction. JAm Soc Nephrol 2006, 17(1):244-253.
66. Cruz D.N., Fard A., Clementi A., et al. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. Semin Nephrol 2012, 32(1):79-92.
67. Tang W.H., Van Lente F., Shrestha K., et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. JCard Fail 2008, 14(5):394-399.
68. Damman K., van Veldhuisen D.J., Navis G., et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008, 10(10):997-1000.
69. Damman K., Kalra P.R., Hillege H. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure. JRen Care 2010, 36(Suppl 1):18-26.
70. Malyszko J., Bachorzewska-Gajewska H., Poniatowski B., et al. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail 2009, 31(10):910-919.
71. Yndestad A., Landrø L., Ueland T., et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009, 30(10):1229-1236.
72. Bolignano D., Basile G., Parisi P., et al. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009, 12(1):7-14.
73. Shrestha K., Borowski A.G., Troughton R.W., et al. Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. JCard Fail 2011, 17(6):472-478.
74. Jungbauer C.G., Birner C., Jung B., et al. Kidney injury molecule-1 and N-acetyl-beta-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011, 13(10):1104-1110.
75. Testani J.M., Kimmel S.E., Dries D.L., et al. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011, 4(6):685-691.
76. Capes S.E., Gerstein H.C., Negassa A., et al. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000, 23(3):377-380.
77. Ljungman S., Kjekshus J., Swedberg K. Renal function in severe congestive heart failure duringtreatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992, 70(4):479-487.
78. Anand I.S., Bishu K., Rector T.S., et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009, 120(16):1577-1584.
79. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999, 341(10):709-717.
80. Zannad F., Dousset B., Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38(5):1227-1232.
81. Wali R.K., Iyengar M., Beck G.J., et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail 2011, 4(1):18-26.
82. Castagno D., Jhund P.S., McMurray J.J., et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis ofthe cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010, 12(6):607-616.
83. Cohen-Solal A., Kotecha D., van Veldhuisen D.J., et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009, 11(9):872-880.
84. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109(13):1594-1602.
85. Boerrigter G., Costello-Boerrigter L.C., Abraham W.T., et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. JCard Fail 2008, 14(7):539-546.
86. Yap S.C., Lee H.T. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. Anesthesiology 2012, 116(5):1139-1148.
87. Prabhu S.D. Cytokine-induced modulation of cardiac function. Circ Res 2004, 95(12):1140-1153.
88. Kingma J.G., Vincent C., Rouleau J.R., et al. Influence of acute renal failure on coronary vasoregulation in dogs. JAm Soc Nephrol 2006, 17(5):1316-1324.
89. Chuasuwan A., Kellum J.A. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012, 32(1):31-39.
90. Grams M.E., Rabb H. The distant organ effects of acute kidney injury. Kidney Int 2012, 81(10):942-948.
91. Ma X.L., Lefer D.J., Lefer A.M., et al. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 1992, 86(3):937-946.
92. Blake P., Hasegawa Y., Khosla M.C., et al. Isolation of "myocardial depressant factor(s)" from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J 1996, 42(5):M911-M915.
93. Edmunds N.J., Lal H., Woodward B. Effects of tumour necrosis factor-alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Br J Pharmacol 1999, 126(1):189-196.
94. Miyano H., Shishido T., Kawada T., et al. Acute effect of tumor necrosis factor-alpha is minimal on mechanics but significant on energetics in blood-perfused canine left ventricles. Crit Care Med 1999, 27(1):168-176.
95. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102(25):3060-3067.
96. Wen X., Peng Z., Li Y., et al. One dose of cyclosporine A is protective at initiation of folic acid-induced acute kidney injury in mice. Nephrol Dial Transplant 2012, 27(8):3100-3109.
97. Verdouw P.D., Gho B.C., Koning M.M., et al. Cardioprotection by ischemic and nonischemic myocardial stress and ischemia in remote organs. Implications for the concept of ischemic preconditioning. Ann N Y Acad Sci 1996, 793:27-42.
98. Kobuchi S., Tanaka R., Shintani T., et al. Mechanisms underlying the renoprotective effect of GABA against ischemia/reperfusion-induced renal injury in rats. JPharmacol Exp Ther 2011, 338(3):767-774.
99. Kajstura J., Cigola E., Malhotra A., et al. Angiotensin II induces apoptosis of adult ventricular myocytes invitro. JMol Cell Cardiol 1997, 29(3):859-870.
100. Nath K.A., Grande J.P., Croatt A.J., et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol 2005, 166(4):963-972.
101. Kelly K.J. Distant effects of experimental renal ischemia/reperfusion injury. JAm Soc Nephrol 2003, 14(6):1549-1558.
102. Wencker D., Chandra M., Nguyen K., et al. Amechanistic role for cardiac myocyte apoptosis in heart failure. JClin Invest 2003, 111(10):1497-1504.
103. Liu Y.H., D'Ambrosio M., Liao T.D., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296(2):H404-H412.
104. Wiedemann H.P., Wheeler A.P., Bernard G.R., et al. Comparison of two fluid-management strategies in acute lung injury. NEngl J Med 2006, 354(24):2564-2575.
105. Payen D., de Pont A.C., Sakr Y., et al. Apositive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008, 12(3):R74.
106. Davis K.L., Laine G.A., Geissler H.J. Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation 2000, 7:269-280.
107. Nazar A., Guevara M., Sitges M., et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. JHepatol 2013, 58(1):51-57.
108. Legrand M., Darmon M., Joannidis M., et al. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med 2013, 39(1):101-108.
109. Nimmo A.J., Than N., Orchard C.H., et al. The effect of acidosis on beta-adrenergic receptors in ferret cardiac muscle. Exp Physiol 1993, 78(1):95-103.
110. Bagshaw S.M., Wald R., Barton J., et al. Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-a prospective multicenter observational study. JCrit Care 2012, 27(3):268-275.
111. Schwenger V., Weigand M.A., Hoffmann O., et al. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury-a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012, 16(4):R140.
112. Neirynck N., Vanholder R., Schepers E., et al. An update on uremic toxins. Int Urol Nephrol 2013, 45(1):139-150.
113. Shannon T.R., Pogwizd S.M., Bers D.M. Elevated sarcoplasmic reticulum Ca2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ Res 2003, 93(7):592-594.
114. Ronco C., Cruz D., Noland B.W. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardio-renal syndrome. Semin Nephrol 2012, 32(1):121-128.
115. Carlsson A.C., Larsson A., Helmersson-Karlqvist J., et al. Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. Eur J Heart Fail 2013, 15(4):441-446.
116. Licurse A., Kim M.C., Dziura J., et al. Renal ultrasonography in the evaluation of acute kidney injury: developing a risk stratification framework. Arch Intern Med 2010, 170:1900-1907.
117. Ozmen C.A., Akin D., Bilek S.U., et al. Ultrasound as a diagnostic tool to differentiate acute from chronic renal failure. Clin Nephrol 2010, 74:46-52.
118. Darmon M., Schortgen F., Vargas F., et al. Diagnostic accuracy of Doppler renal resistive index for reversibility of acute kidney injury in critically ill patients. Intensive Care Med 2011, 37(1):68-76.
119. James M.T., Ghali W.A., Knudtson M.L., et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011, 123(4):409-416.
120. Selby N.M., Kolhe N.V., McIntyre C.W., et al. Defining the cause of death in hospitalised patients with acute kidney injury. PLoS One 2012, 7(11):e48580.
121. Jasuja D., Mor M.K., Hartwig K.C., et al. Provider knowledge of contrast-induced acute kidney injury. Am J Med Sci 2009, 338:280-286.
122. Solomon R.J., Mehran R., Natarajan M.K., et al. Contrast-induced nephropathy and long-term adverse events: cause and effect?. Clin J Am Soc Nephrol 2009, 4:1162-1169.
123. Mentzer R.M., Oz M.C., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. JAm Coll Cardiol 2007, 49:716-726.
124. Redóna J., Cea-Calvob L., Lozanoc J.V., et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. JHypertens 2006, 24:663-669.
125. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. NEngl J Med 2004, 351:1285-1295.
126. Rostand S.G., Kirk K.A., Rutsky E.A. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984, 25:653-659.
127. Joki N., Hase H., Nakamura R. Onset of coronary artery disease prior to initiation of hemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997, 12:718-723.
128. Whalley G.A., Marwick T.H., Doughty R.N., et al. IDEAL effect of early initiation of dialysis on cardiac structure and function: results from the echo substudy of the IDEAL Trial. Am J Kidney Dis 2013, 61(2):262-270.
129. Chonchol M., Whittle J. Desbien: chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 2008, 28:354-360.
130. McCullough P.A., Agrawal V., Danielewicz E., et al. Accelerated atherosclerotic calcification and Mönckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1585-1598.
131. Gross M.L., Meyer H.P., Ziebart H., et al. Calcification of coronary intima and media. Clin J Am Soc Nephrol 2007, 2:121-134.
132. Ragosta M., Samady H., Isaacs R.B., et al. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries. Am Heart J 2004, 147:1017-1023.
133. Garland J.S., Holden R.M., Groome P.A., et al. Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. Am J Kidney Dis 2008, 52:849-858.
134. Adragao T., Pires A., Branco P., et al. Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant 2012, 27:318-325.
135. Moe S.M., O'Neill K.D., Duan D., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002, 61:638-647.
136. Campean V., Nonnast-Daniel B., Garlichs C., et al. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 2007, 190:156-166.
137. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
138. McGregor E., Jardine A.G., Murray L.S., et al. Preoperative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant 1998, 13:1499-1505.
139. Foley R.N., Parfey P.S., Harneyf J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47:186-192.
140. Foley R.N., Curtis B.M., Randell E.W., et al. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010, 5:805-813.
141. McIntyre C.W., Burton J.O., Selby N.M., et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008, 3:19-26.
142. Parfey P.S., Harnett J.D., Foley R.N. Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hypertens 1995, 4:105-110.
143. Blancher J., Safar M.E., Guerin A.P., et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003, 63:1852-1860.
144. Bogrov A.Y., Shapiro J.I. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008, 4:378-392.
145. Amann K., Breitbach M., Ritz E., et al. Myocyte/capillary mismatch in the heart of uremic patients. JAm Soc Nephrol 1998, 9:1018-1022.
146. Mall G., Huther W., Schneider J., et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990, 5:39-44.
147. Meert N., Schepers E., De Smet R., et al. Inconsistency of reported uremic toxin concentrations. Artif Organs 2007, 31:600-611.
148. Miyazaki T., Ise M., Seo H., et al. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997, 62:S15-S22.
149. Sharma U.C., Pokharel S., van Brakel T.J. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contribute to cardiac dysfunction. Circulation 2004, 110:3121-3128.
150. Lok D.J., Van Der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
151. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
152. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAm Heart Assoc 2012, 1:1-7.
153. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. JClin Invest 2011, 121:4393-4408.
154. Gutiérrez O.M., Januzzi J.L., Isakova T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
155. Di Lullo L., Floccari F., Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 2011, 118:c258-c262.
156. McCullough P.A. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?. JAm Coll Cardiol 2003, 41(5):725-728.
157. Kalantar-Zadeh K., Block G., Humphreys M.H., et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63(3):793-808.
158. Di Lullo L., Floccari F., Santoboni A., et al. Progression of cardiac valve calcification and decline of renal function in CKD patients. JNephrol 2013, 26(4):739-744.
159. Dmitrieva O., de Lusignan S., Macdougall I.C., et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013, 14:24.
160. EVOLVE Trial Investigators, Chertow G.M., Block G.A., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. NEngl J Med 2012, 367(26):2482-2494.
161. Baigent C., Landray M.J., Reith C., SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
162. Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(5 Suppl 1):S1-S290.
163. Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12-S154.
164. Kidney Disease Improving Global Outcomes (KDIGO) Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 2009, 76(Suppl 113):S50-S69.
165. Herzog C.A., Mangrum J.M., Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008, 21(4):300-307.
166. Ronco C., McCullough P.A., Anker S.D., Acute Dialysis Quality Initiative (ADQI) consensus group, et al. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010, 165:54-67.
167. Lundy D.J., Trzeciak S. Microcirculatory dysfunction in sepsis. Crit Care Clin 2009, 25(4):721-731.
168. Trzeciak S., Dellinger R.P., Parrillo J.E., et al. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 2007, 49(1):88-98. 98.e1-2.
169. Jardin F., Brun-Ney D., Auvert B., et al. Sepsis-related cardiogenic shock. Crit Care Med 1990, 18(10):1055-1060.
170. Lambermont B., Ghuysen A., Kolh P., et al. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 2003, 59(2):412-418.
171. Parker M.M., Shelhamer J.H., Bacharach S.L., et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100(4):483-490.
172. Dhainaut J.F., Huyghebaert M.F., Monsallier J.F., et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987, 75(3):533-541.
173. Kumar A., Thota V., Dee L., et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for invitro myocardial cell depression induced by human septic shock serum. JExp Med 1996, 183(3):949-958.
174. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). JAm Coll Cardiol 1996, 27(5):1201-1206.
175. Benes J., Chvojka J., Sykora R., et al. Searching for mechanisms that matter in early septic acute kidney injury: an experimental study. Crit Care 2011, 15(5):R256.
176. Bougle A., Duranteau J. Pathophysiology of sepsis-induced acute kidney injury: the role of global renal blood flow and renal vascular resistance. Contrib Nephrol 2011, 174:89-97.
177. Schmidt H., Hoyer D., Hennen R., et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med 2008, 36(3):967-970.
178. Tateishi Y., Oda S., Nakamura M., et al. Depressed heart rate variability is associated with high IL-6 blood level and decline in the blood pressure in septic patients. Shock 2007, 28(5):549-553.
179. Ramchandra R., Wan L., Hood S.G., et al. Septic shock induces distinct changes in sympathetic nerve activity to the heart and kidney in conscious sheep. Am J Physiol Regul Integr Comp Physiol 2009, 297(5):R1247-R1253.
180. Doerschug K.C., Delsing A.S., Schmidt G.A., et al. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 2010, 14(1):R24.
181. Shen L., Mo H., Cai L., et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 2009, 31(5):500-506.
182. Hagiwara S., Iwasaka H., Matumoto S., et al. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in invivo and invitro models. Crit Care Med 2009, 37(2):626-633.
183. Mortensen E.M., Iwasaka H., Matumoto S., et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007, 27(12):1619-1626.
184. Soni A., Pepper G.M., Wyrwinski P.M., et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995, 98(3):266-271.
185. Sligl W.I., Milner D.A., Sundar S., et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009, 49(1):93-101.
186. Burchill L., Velkoska E., Dean R.G., et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 2008, 93(5):622-630.
187. Tokuyama H., Kelly D.J., Zhang Y., et al. Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol 2007, 106(3):p54-p62.
188. Chopra M., Golden H.B., Mullapudi S., et al. Modulation of myocardial mitochondrial mechanisms during severe polymicrobial sepsis in the rat. PLoS One 2011, 6(6):e21285.
189. Liu M., Grigoryev D.N., Crow M.T., et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 2009, 76(3):277-285.
190. Celes M.R., Prado C.M., Rossi M.A. Sepsis: going to the heart of the matter. Pathobiology 2013, 80(2):70-86.
191. Stengl M., Bartak F., Sykora R., et al. Reduced L-type calcium current in ventricular myocytes from pigs with hyperdynamic septic shock. Crit Care Med 2010, 38(2):579-587.
192. Good D.W., George T., Watts B.A. Toll-like receptor 2 mediates inhibition of HCO(3)(-) absorption by bacterial lipoprotein in medullary thick ascending limb. Am J Physiol Renal Physiol 2010, 299(3):F536-F544.
193. Schreiber A., Theilig F., Schweda F., et al. Acute endotoxemia in mice induces downregulation of megalin and cubilin in the kidney. Kidney Int 2012, 82(1):53-59.
194. Reinhart K., Bauer M., Riedemann N.C., et al. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012, 25(4):609-634.
195. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327.
196. Vignon P., Frank M.B., Lesage J., et al. Hand-held echocardiography with Doppler capability for the assessment of critically-ill patients: is it reliable?. Intensive Care Med 2004, 30(4):718-723.
197. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8(4):R204-R212.
198. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31.
199. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012, 120(4):179-184.
200. Calvin J.E., Driedger A.A., Sibbald W.J. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest 1981, 80(5):579-586.
201. Liu K.D., Thompson B.T., Ancukiewicz M., et al. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med 2011, 39(12):2665-2671.
202. Bellomo R., Prowle J.R., Echeverri J.E., et al. Fluid management in septic acute kidney injury and cardiorenal syndromes. Contrib Nephrol 2010, 165:206-218.
203. De Vriese A.S., Colardyn F.A., Philippé J.J., et al. Cytokine removal during continuous hemofiltration in septic patients. JAm Soc Nephrol 1999, 10(4):846-853.
204. Tapia P., Chinchón E., Morales D., et al. Effectiveness of short-term 6-hour high-volume hemofiltration during refractory severe septic shock. JTrauma Acute Care Surg 2012, 72(5):1228-1237. [discussion: 1237-8].
205. Matson J., Zydney A., Honore P.M. Blood filtration: new opportunities and the implications of systems biology. Crit Care Resusc 2004, 6(3):209-217.
206. Nakamura M., Oda S., Sadahiro T., et al. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol 2010, 166:73-82.
207. Cruz D.N., Antonelli M., Fumagalli R., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301(23):2445-2452.
208. Humes H.D., Antonelli M., Fumagalli R., et al. Aselective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure. Blood Purif 2010, 29(2):183-190.
209. Hou Z.Q., Sun Z.X., Su C.Y., et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther 2012, 10.1111/cdr.12001.
210. Ristikankare A., Pöyhiä R., Eriksson H., et al. Effects of levosimendan on renal function in patients undergoing coronary artery surgery. JCardiothorac Vasc Anesth 2012, 26(4):591-595.
211. Chou Y.H., Huang T.M., Wu V.C., et al. Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. Crit Care 2011, 15(3):R134.
212. Bellomo R., Wan L., May C. Vasoactive drugs and acute kidney injury. Crit Care Med 2008, 36(Suppl 4):S179-S186.
213. Schmoelz M., Schelling G., Dunker M., et al. Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine-treated septic shock. JCardiothorac Vasc Anesth 2006, 20(2):173-178.
214. Cobas M., Paparcuri G., De La Pena M., et al. Fenoldopam in critically ill patients with early renal dysfunction. A crossover study. Cardiovasc Ther 2011, 29(4):280-284.
215. Landoni G., et al. Fenoldopam in cardiac surgery-associated acute kidney injury. Int J Artif Organs 2008, 31(6):561.
216. Redfors B., Bragadottir G., Sellgren J., et al. Effects of norepinephrine on renal perfusion, filtration and oxygenation in vasodilatory shock and acute kidney injury. Intensive Care Med 2011, 37(1):60-67.
217. Guzman J.A., Rosado A.E., Kruse J.A. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. JAppl Physiol (1985) 2003, 95(2):803-809.
218. Gordon A.C., Russell J.A., Walley K.R., et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010, 36(1):83-91.
219. Nigwekar S.U., Waikar S.S. Diuretics in acute kidney injury. Semin Nephrol 2011, 31(6):523-534.